Table 1 Clinical trials on TAMs (from https://clinicaltrials.gov/)
From: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
Action | Agent | Combination | Target | Status | Tumor type | Clinical trial number |
|---|---|---|---|---|---|---|
Inhibiting the recruitment of TAMs | Carlumab | NA | CCL2 | Completed II | Prostate cancer | NCT00992186 |
CNTO 888(mAb) | Gemcitabine Paclitaxel and carboplatin docetaxel | CCL2 | Completed I | Solid tumors | NCT01204996 | |
CNTO 888(mAb) | NA | CCL2 | Completed I | Solid tumors | NCT00537368 | |
PF-04136309 | FOLFIRINOX* | CCR2 | Completed I | Pancreatic neoplasms | NCT01413022 | |
MLN1202 | NA | CCR2 | Completed II | Bone metastases | NCT01015560 | |
Activating TAMs | MCS110 | Carboplatin and Gemcitabine | CSF-1 | Completed II | Triple-negative breast cancer | NCT02435680 |
MCS110 | Placebo | CSF-1 | Completed II | Cancer | NCT01643850 | |
MCS110 | NA | CSF-1 | Terminated I/II | Prostate cancer, Bone Metastases | NCT00757757 | |
IMC-CS4 (LY3022855) | NA | CSF-1R | Completed I | Solid tumors | NCT01346358 | |
IMC-CS4 | NA | CSF-1R | Completed I | Breast or Prostate cancer | NCT02265536 | |
AMG 820 | NA | CSF-1R | Completed I | Solid tumors | NCT01444404 | |
AMG 820 | pembrolizumab | CSF-1R | Completed I/II | Pancreatic cancer, Colorectal cancer, Non-small cell lung cancer | NCT02713529 | |
Emactuzumab | Atezolizumab | CSF-1R PD-L1 | Completed Ib | Solid tumors | NCT02323191 | |
ARRY-382 | Pembrolizumab | CSF-1R PD-1 | Completed I b/II | Solid tumors | NCT02880371 | |
Pexidartinib | Durvalumab | CSF-1R PD-L1 | Completed I | Pancreatic or Colorectal cancers | NCT02777710 | |
SNDX-6352 | Durvalumab | CSF-1R PD-L1 | Active, not recruiting I | Solid tumors | NCT03238027 | |
BLZ945 | PDR001 | CSF-1R PD-1 | Active, not recruiting I/II | Solid tumors | NCT02829723 | |
Cabiralizumab (BMS-986227, FPA008) | Nivolumab (BMS-936558) | CSF-1R PD-1 | Completed I | Malignancies | NCT03158272 | |
Trabectedin | Durvalumab (MEDI4736) | PD-L1 | Active, not recruiting Ib | Soft-tissue sarcomas and ovarian carcinomas | NCT03085225 | |
PLX7486 | NA | CSF-1R | Terminated I | Solid tumors | NCT01804530 | |
PLX3397 (Pexidartinib) | NA | CSF-1R | Terminated II | Glioblastoma | NCT01349036 | |
PLX3397 | NA | CSF-1R | Completed II | Hodgkin lymphoma | NCT01217229 | |
PLX3397 | NA | CSF-1R | Terminated II | Prostate cancer | NCT01499043 | |
PLX3397 | Sirolimus | CSF-1R | Recruiting I Recruiting II | Sarcoma Malignant Peripheral Nerve Sheath Tumors | NCT02584647 | |
PLX3397 | Pembrolizumab | CSF-1R | Terminated I/II | Tumors* | NCT02452424 | |
PLX3397 | Eribulin | CSF-1R | Completed I b/II | Breast cancer | NCT01596751 | |
PLX3397(Turalio) | NA | Â | Recruiting I/II | Leukemias, Solid tumors | NCT02390752 | |
PLX3397 (Pexidartinib) | Paclitaxel (Onxol) | Â | Completed I | Solid tumors | NCT01525602 | |
Alemtuzumab | NA | CD52 | Terminated I | Ovarian/primary peritoneal cancer | NCT00637390 | |
Alemtuzumab | fludarabine and cyclophosphamide | CD52 | Completed II | Kidney cancer | NCT00073879 | |
Reprogramming TAMs | Chi Lob 7/4 | NA | CD40 | Completed I | Malignancies | NCT01561911 |
GM.CD40L* Vaccine | CCL21 | CD40 | Completed I/II | Lung cancer, Adenocarcinoma | NCT01433172 | |
CP-870,893* | NA | CD40 | Completed I | Advanced solid tumors | NCT02225002 | |
CP-870,893 | Tremelimumab* | CD40 | Completed I | Melanoma | NCT01103635 | |
CP-870,893 | Paclitaxel + Carboplatin | CD40 | Completed I | Neoplasms | NCT00607048 | |
CP-870,893 | Gemcitabine | CD40 | Completed I | Adenocarcinoma pancreas | NCT01456585 | |
RO7009789 | Emactuzumab (RO5509554) | CD40 | Completed I | Neoplasms | NCT02760797 | |
RO7009789 | nab-paclitaxel, gemcitabine | CD40 | Completed I | Pancreatic cancer | NCT02588443 | |
RO7009789 | Vanucizumab, Bevacizumab | CD40 | Completed I | Solid tumors | NCT02665416 | |
Selicrelumab (RO7009789) | Atezolizumab | CD40 PD-1 | Completed I | Solid tumors | NCT02304393 | |
APX005M | Nivolumab | CD40 | Completed I/II | Non-small cell lung cancer, Metastatic Melanoma | NCT03123783 | |
IPI-549 | Nivolumab | PI3K-γ PD-1 | Active, not recruiting I | Solid tumors, non-small cell lung cancer, melanoma, breast cancer | NCT02637531 | |
TTI-621 | PD-1/PD-L1 Inhibitor* pegylated interferon-α2a talimogene laherparepvec (T-Vec) radiation | SIRPα-IgG1 Fc | Terminated I | Solid Tumors, Mycosis fungoides, Melanoma, Merkel-cell carcinoma, Squamous cell carcinoma, Breast carcinoma, Human papillomavirus-related malignant neoplasm, Soft tissue sarcoma | NCT02890368 | |
Hu5F9-G4 | Atezolizumab | CD47 | Completed I | Acute myeloid leukemia | NCT03922477 | |
CC-90002 | NA | CD47 | Terminated I | Leukemia, Myeloid, Acute myelodysplastic syndromes | NCT02641002 | |
CC-90002 | Rituximab | CD47 | Completed I | Hematologic neoplasms | NCT02367196 | |
GSK3145095 | pembrolizumab | RIP | Terminated II | Neoplasms, Pancreatic | NCT03681951 | |
NKTR-262 | Bempegaldesleukin (NKTR-214) Nivolumab | TLR7/8 PD-1 | Active, not recruiting I/II | Solid tumors | NCT03435640 | |
WP1066 | NA | STAT3 | Active, not recruiting I | Glioma and Brain metastasis from melanoma | NCT01904123 | |
AZD9150 (ISIS 481464) | NA | STAT3 | Completed I/Ib | Advanced/Metastatic Hepatocellular carcinoma | NCT01839604 | |
Imprime PGG | Cetuximab | MAPK | Completed II | Colorectal Cancer | NCT00912327 | |
Immunological Adjuvant OPT-821 | β-glucan |  | Active, not recruiting I/II | Neuroblastoma | NCT00911560 | |
β-Glucan | Anti-GD2 Monoclonal Antibody 3F8 |  | Active, not recruiting I | Neuroblastoma | NCT00492167 |